GlassScriptPhysician profile
James V Agresti
NPI 1255389813
$4,220.21
in general payments reported to CMS, 2019-2025
51 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $630 · 2021: $358 · 2022: $793 · 2023: $682 · 2024: $405 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $671.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $375.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.21 | 2020-2025 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $240.63 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.35 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $147.89 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $130.05 | 2019-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $127.98 | 2019-2022 | |
| Almatica Pharma LLC | $121.57 | 2021-2024 | Loreev Xr, Gralise |
| Abbvie INC. | $118.52 | 2019-2024 | Linzess, Synthroid |
| Janssen Pharmaceuticals, INC | $117.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $116.85 | 2020-2024 | Farxiga |
| Cumberland Pharmaceuticals, INC. | $101.70 | 2022-2025 | Kristalose |
| Kowa Pharmaceuticals America, INC. | $94.11 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $89.99 | 2021-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Agresti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.